Semaglutide 'unexpected changes': what TikTok gets right and wrong

What did @realdrbae actually say?

The creator, identifying as a doctor affiliated with a telehealth network, listed three "unexpected" benefits patients are experiencing on semaglutide: improved sleep apnea, reduced impulsive behaviors (drinking, smoking, nail-biting, online shopping), and lower anxiety and depression. The framing was enthusiastic and anecdotal, leaning on patient reports and one colleague's clinical practice rather than citing any research directly. The claim that an ENT in their network is now treating sleep apnea "with semaglutide" instead of CPAP is the one that raised the most flags for me. The other two claims land somewhere between reasonable and overstated, depending on how you read the evidence.

Does the science back this up?

On sleep apnea, yes, there is real data here. The SURMOUNT-OSA trial (Patwardhan et al., 2024, NEJM) showed that tirzepatide, not semaglutide specifically, significantly reduced apnea-hypopnea index scores in adults with obesity-related obstructive sleep apnea. Semaglutide has shown similar weight-loss driven improvements in smaller studies, and the FDA approved tirzepatide for sleep apnea in 2024, a first for this drug class. So the mechanism is plausible and documented. On impulse control, the picture is murkier but genuinely interesting. GLP-1 receptors exist in reward-related brain regions, and animal studies have shown reduced alcohol and nicotine seeking behavior. A 2023 observational study by Klausen et al. in eClinicalMedicine found lower alcohol use disorder rates among GLP-1 users, though causality is far from settled. On anxiety and depression, the evidence is mostly indirect. Weight loss itself is associated with mood improvements, and some small trials suggest GLP-1 agonists may have direct neurological effects, but nothing conclusive in humans yet.

What did they get wrong (or right)?

The sleep apnea framing is where this video does the most damage. Saying a doctor now treats patients "with semaglutide" instead of CPAP suggests a like-for-like swap, and that is not how any of this works. GLP-1 agonists address obesity-related sleep apnea by reducing weight, and they do not treat apnea in patients where obesity is not the primary driver. CPAP remains the standard of care for moderate-to-severe OSA. Presenting weight loss as a replacement for CPAP, without any of those qualifications, is irresponsible framing from someone who claims clinical authority. The impulse control section gets partial credit. The nail-biting and online shopping examples are pure anecdote, but the alcohol and smoking observations are consistent with emerging research. Lumping serious behavioral changes in with online shopping makes the whole claim feel less credible than it should. The anxiety and depression section is the most defensible of the three, but "less anxious and less depressed" as a semaglutide effect conflates weight loss benefits with any direct pharmacological action, and the video does not distinguish between the two.

What should you actually know?

GLP-1 receptor agonists like semaglutide are showing up in research areas well beyond blood sugar and weight, and that is genuinely worth paying attention to. But a TikTok built on anecdotes from a single practice, presented without study citations or clinical nuance, is not a reliable way to evaluate those possibilities. If you have sleep apnea, do not stop using CPAP because of this video. If you have noticed changes in cravings or mood on semaglutide, that is worth discussing with your prescriber, because those observations may be real, but they are not reasons to self-adjust your treatment. The research on GLP-1 effects on addiction and mental health is active and promising, with clinical trials underway for alcohol use disorder and depression. Watching that space is reasonable. Taking medical direction from a viral TikTok is not.

Is there a conflict of interest worth noting?

The creator references their own telehealth network, Dr. Well, multiple times in a short video. This is a promotional context, not a neutral educational one. That does not automatically make the claims false, but it does mean the framing is designed to build confidence in their platform and services. Viewers should weigh that when deciding how much authority to extend to the clinical observations being shared.